Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase II trials of Xenova's P-gp pump inhibitor planned in U.S. and U.K.

Dec. 16, 1998

Clinical studies support excellent safety and efficacy of Busulfex

Dec. 15, 1998

New antitumor compounds presented by Kyorin

Dec. 15, 1998

Oxigene describes mechanism of action, therapeutic potential of declopramide

Dec. 15, 1998

Celgene acquires EntreMed rights to thalidomide

Dec. 14, 1998

AEterna signs CTA with NCI and reports lung cancer pivotal trial protocol details

Dec. 14, 1998

Dendritic cell therapies based on Dendreon technology focus of Dendreon-Kirin partnership

Dec. 14, 1998

Decitabine considered a promising treatment option for high-risk patients with MDS

Dec. 11, 1998

Mouse studies indicate that IL-12 gene therapy is a feasible and effective treatment for AML

Dec. 11, 1998

DDE-261: a novel gigantecin analogue in early development at Wayne Hughes Institute

Dec. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...